Figure 3. Meta-analysis of the use of angiotensin receptor blockers (ARBs) on pneumonia risk. The risk of pneumonia was not significantly different between patients who did or did not use ARBs (OR, 0.90; 95% CI, 0.79 to 1.02; p=0.11).